ArticleEuropean radiology2020
Comprehensive analyses with radiological and biological markers of breast cancer on contrast-enhanced chest CT: a single center experience using dual-layer spectral detector CT.
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Spectral CT-based radiomics signature for distinguishing malignant pulmonary nodules from benign.BMC cancer · 2023Trial
- Lesion conspicuity assessment of prone 40-keV virtual monoenergetic imaging in arterial-phase photon-counting CT for breast cancer: a retrospective comparison with DCE-MRI.Japanese journal of radiology · 2026Article
- Dual-layer spectral detector computed tomography-derived virtual non-contrast images in breast cancer patients: a promising alternative to true non-contrast images.Quantitative imaging in medicine and surgery · 2025Article
- Predict status of axillary lymph node after neoadjuvant chemotherapy with dual-energy CT in breast cancer.BMC medical imaging · 2025Article
- A prediction model based on dual-layer spectral detector computed tomography for distinguishing nonluminal from luminal invasive breast cancer.Quantitative imaging in medicine and surgery · 2024Article
- Differentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation.Insights into imaging · 2024Article
- The diagnostic performance of dual-layer spectral detector CT for distinguishing breast cancer biomarker expression and molecular subtypes.Scientific reports · 2024Article
- Dual-Energy CT in Breast Cancer: Current Applications and Future Outlooks.Precision radiation oncology · 2023Review
- Thoracic Diseases: Technique and Applications of Dual-Energy CT.Diagnostics (Basel, Switzerland) · 2023Review
- Predicting axillary lymph node metastasis in breast cancer using the similarity of quantitative dual-energy CT parameters between the primary lesion and axillary lymph node.Japanese journal of radiology · 2022Article
- Detection of axillary lymph node metastasis in breast cancer using dual-layer spectral computed tomography.Frontiers in oncology · 2022Article
- Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis.Gland surgery · 2020Review
- Clinical Feasibility of Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging with Computed Diffusion-Weighted Imaging Technique in Breast Cancer Patients.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the predictive value of virtual monoenergetic images (VMIs) by assessing tumor conspicuity on dual-layer spectral detector CT (SDCT) and correlate tumor conspicuity on VMI with prognostic biomarkers in patients with breast cancer.
methodsSixty-four patients underwent arterial phase and 90-s delayed phase dual-layer SDCT. A retrospective tumor conspicuity analysis of 14 benign tumors and 65 breast cancers was performed using conventional images (CIs) and VMI at 40 keV (VMI40) on arterial and delayed phase scans (CI
resultsCancers on VMI40 had a significantly higher conspicuity score and mean HU than benign tumors (p < 0.001). VMI40
conclusionsVMI40 KEY POINTS: • VMI40 improved conspicuity of breast cancer than CI. • VMI40
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.